PYOTT DAVID E I sold $5K of ALNY
PYOTT DAVID E I sold 17 shares of ALNYLAM PHARMACEUTICALS, INC. (ALNY) at $302.65 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the transaction is under a pre-arranged 10b5-1 plan and is small, it is unlikely to materially change ALNY fundamentals or expectations.
Market read
A scheduled director sale is disclosed; treat as low-signal unless paired with other catalysts or additional insider changes.
What to watch
The sale size is very small (17 shares), and the disclosure does not indicate intent beyond the pre-arranged plan.
Background
SEC Form 4 disclosures report insider trades; 10b5-1 plans are pre-arranged to reduce timing-based trading concerns.
Ticker impact
Alnylam director David E. Pyott sold $5,145 of ALNY shares in an open-market transaction under a pre-arranged 10b5-1 plan.
Low near-term impact; any reaction is likely muted versus non-10b5-1 sales.
The filing provides a small, scheduled sale (17 shares) rather than an unscheduled change in insider behavior.
Market effects
No clear sector read-through from a small, scheduled insider sale.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with periods of perceived risk; traders may still watch for follow-on insider activity.
Key entities
- issuerALNYLAM PHARMACEUTICALS, INC.
Subject of the Form 4 insider transaction disclosure.
- directorPYOTT DAVID E I
Director who sold 17 ALNY shares on June 1, 2026 under a 10b5-1 plan.
